Dunlop A. Sinclair
Insider CIK 1721108 · APLS Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 14,684 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 27,600 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 7,441 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 27,600 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 5,748 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 11,199 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 8,554 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 5,744 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 7,961 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 3,544 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 3,062 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | U Tender | 2026-05-14 | 2026-05-14 | 161,567 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2026-01-01 | 2026-01-05 | 14,684 | — | $0 | 14,684 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-01-01 | 2026-01-05 | 7,961 | — | $0 | 161,567 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-10-10 | 2025-10-15 | 31,092 | $23.72 | $737.5K | 3,837 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2025-10-10 | 2025-10-15 | 3,837 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2025-09-30 | 2025-10-02 | 3,837 | — | $0 | 30,142 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-09-30 | 2025-10-02 | 31,092 | $22.58 | $702.1K | 33,979 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2025-09-19 | 2025-09-19 | 3,837 | — | $0 | 65,071 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-09-19 | 2025-09-19 | 31,092 | $22.95 | $713.6K | 68,908 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2025-06-24 | 2025-10-15 | 4,787 | — | $0 | 153,606 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2025-01-01 | 2025-01-03 | 11,199 | — | $0 | 11,199 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2025-01-01 | 2025-01-03 | 6,267 | — | $0 | 158,393 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2024-09-23 | 2024-09-24 | 4,600 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2024-09-23 | 2024-09-24 | 4,600 | $13.19 | $60.7K | 152,126 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-09-16 | 2024-09-17 | 7,524 | $36.79 | $276.8K | 100,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-09-16 | 2024-09-17 | 29,476 | $36.09 | $1.06M | 107,524 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2024-06-28 | 2024-07-01 | 900 | — | $0 | 4,600 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2024-06-28 | 2024-07-01 | 900 | $13.19 | $11.9K | 134,418 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-06-21 | 2024-06-21 | 35,305 | $39.22 | $1.38M | 138,693 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-06-21 | 2024-06-21 | 1,695 | $39.63 | $67.2K | 136,998 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2024-04-12 | 2024-04-15 | 1,500 | — | $0 | 5,500 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2024-04-12 | 2024-04-15 | 1,500 | $13.19 | $19.8K | 133,518 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-03-19 | 2024-03-20 | 18,681 | $57.18 | $1.07M | 173,998 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2024-01-01 | 2024-01-02 | 5,748 | $59.86 | $344.1K | 5,748 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2024-01-01 | 2024-01-02 | 3,341 | — | $0 | 132,018 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2023-12-14 | 2023-12-15 | 6,274 | — | $0 | 7,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2023-12-14 | 2023-12-15 | 6,274 | $13.19 | $82.8K | 128,677 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-12-01 | 2023-12-05 | 24,000 | $61.14 | $1.47M | 192,679 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-11-17 | 2023-11-21 | 8,894 | $49.99 | $444.6K | 122,403 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-10-17 | 2023-11-21 | 24,000 | $49.00 | $1.18M | 216,679 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-04-03 | 2023-04-05 | 500 | $74.05 | $37.0K | 131,297 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-03-01 | 2023-03-02 | 500 | $65.33 | $32.7K | 131,797 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-02-01 | 2023-02-02 | 500 | $52.61 | $26.3K | 132,297 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-01-03 | 2023-01-05 | 500 | $50.70 | $25.4K | 132,797 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2023-01-01 | 2023-01-04 | 7,441 | — | $0 | 7,441 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2023-01-01 | 2023-01-04 | 3,867 | — | $0 | 133,297 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-12-01 | 2022-12-02 | 500 | $49.93 | $25.0K | 129,430 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-11-01 | 2022-11-03 | 500 | $60.83 | $30.4K | 129,930 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-09-08 | 2022-09-08 | 15,000 | $65.00 | $975.0K | 240,679 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-08-25 | 2022-08-26 | 4,306 | — | $0 | 13,274 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-08-25 | 2022-08-26 | 4,306 | $13.19 | $56.8K | 130,430 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-08-16 | 2022-08-17 | 25,394 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-08-16 | 2022-08-17 | 25,394 | $14.00 | $355.5K | 126,124 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-08-11 | 2022-08-12 | 30,000 | $65.63 | $1.97M | 255,679 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-07-21 | 2022-07-22 | 9,606 | — | $0 | 25,394 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-07-21 | 2022-07-22 | 9,606 | $14.00 | $134.5K | 100,730 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-06-27 | 2022-06-29 | 1,341 | $46.79 | $62.7K | 1,341 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-06-23 | 2022-06-24 | 15,000 | $45.00 | $675.0K | 285,679 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-04-22 | 2022-04-25 | 20,000 | — | $0 | 35,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-04-22 | 2022-04-25 | 20,000 | $14.00 | $280.0K | 91,124 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2022-01-01 | 2022-01-04 | 8,554 | — | $0 | 8,554 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2022-01-01 | 2022-01-04 | 4,230 | — | $0 | 71,124 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2021-09-10 | 2021-09-13 | 6,894 | — | $0 | 55,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2021-09-10 | 2021-09-13 | 6,894 | $14.00 | $96.5K | 66,894 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2021-06-01 | 2021-06-02 | 2,682 | — | $0 | 303,361 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2021-06-01 | 2021-06-02 | 13,108 | — | $0 | 73,108 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2021-06-01 | 2021-06-02 | 31,855 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-05-20 | 2021-05-20 | 5,773 | $48.10 | $277.7K | 31,855 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-05-19 | 2021-05-20 | 7,612 | $50.00 | $380.6K | 300,679 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-05-18 | 2021-05-20 | 64,179 | $51.66 | $3.32M | 110,549 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-05-18 | 2021-05-20 | 800 | $54.02 | $43.2K | 308,291 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-05-18 | 2021-05-20 | 10,388 | $53.50 | $555.8K | 309,091 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-05-18 | 2021-05-20 | 1,200 | $52.01 | $62.4K | 319,479 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-05-18 | 2021-05-20 | 14,216 | $52.63 | $748.2K | 96,333 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-05-18 | 2021-05-20 | 36,387 | $53.78 | $1.96M | 59,946 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-05-18 | 2021-05-20 | 22,318 | $54.57 | $1.22M | 37,628 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2021-04-23 | 2021-04-26 | 10,000 | — | $0 | 61,894 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2021-04-23 | 2021-04-26 | 10,000 | $14.00 | $140.0K | 60,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2021-04-16 | 2021-04-19 | 50,000 | — | $0 | 71,894 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2021-04-16 | 2021-04-19 | 50,000 | $14.00 | $700.0K | 50,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2021-01-01 | 2021-01-04 | 27,600 | — | $0 | 27,600 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2020-12-14 | 2020-12-15 | 17,132 | $55.01 | $942.4K | 174,942 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2020-12-14 | 2020-12-15 | 7,654 | $53.86 | $412.2K | 192,074 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2020-12-14 | 2020-12-15 | 214 | $56.25 | $12.0K | 174,728 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2020-12-07 | 2020-12-07 | 9,094 | $50.41 | $458.4K | 209,198 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2020-12-07 | 2020-12-07 | 9,470 | $51.00 | $483.0K | 199,728 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2020-12-04 | 2020-12-07 | 1,384 | $51.05 | $70.7K | 218,292 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2020-12-04 | 2020-12-07 | 5,052 | $50.04 | $252.8K | 219,676 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2020-01-01 | 2020-01-03 | 27,600 | $30.62 | $845.1K | 27,600 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2019-12-20 | 2019-12-20 | 25,000 | $29.53 | $738.3K | 224,728 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2019-12-19 | 2019-12-20 | 54,110 | $28.99 | $1.57M | 320,681 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2019-12-19 | 2019-12-20 | 31,000 | $29.51 | $914.8K | 249,728 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2019-12-18 | 2019-12-20 | 25,890 | $28.55 | $739.2K | 374,791 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2019-01-01 | 2019-01-03 | 17,580 | — | $0 | 17,580 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2018-05-07 | 2018-05-09 | 94,357 | — | $0 | 280,728 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | C Conversion deriv | 2017-11-13 | 2017-11-13 | 31,478 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | C Conversion deriv | 2017-11-13 | 2017-11-13 | 150,023 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | C Conversion deriv | 2017-11-13 | 2017-11-13 | 6,078 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | C Conversion deriv | 2017-11-13 | 2017-11-13 | 213,100 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | C Conversion | 2017-11-13 | 2017-11-13 | 400,679 | — | $0 | 400,679 | SEC↗ |